Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV ...

Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...

Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the ...

Pharmaron Biologics, Liverpool, UK, is a commercial development and manufacturing organization (CDMO) that offers a range of unique end-to-end laboratory services for the development and manufacture ...

HOLLISTER, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...

Trisk Bio Ltd, a UK-based AAV contract development and manufacturing organisation (CDMO), and NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy, today announced ...

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. ...

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

HOLLISTER, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (TKNO), a leading producer of critical reagents for the research, discovery, development ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...